secwatch.observer — SEC 8-K summary
======================================

Issuer:     Z Squared Inc. (ZSQR)
CIK:        0001759186
Form:       8-K
Filed at:   2024-09-19T23:59:59+00:00
Accession:  0001683168-24-006521
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coeptis Therapeutics gets Nasdaq extension to Jan 15, 2025 to regain $1 bid price compliance
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel granted continued listing through Jan 15, 2025, subject to compliance with Minimum Bid Price Requirement.
- Company plans to implement a reverse stock split to regain compliance.
- Original non-compliance notice received Jan 29, 2024; previous compliance period ended July 29, 2024.
- CEO Dave Mehalick expressed optimism about regaining and maintaining Nasdaq listing.
- Extension follows a hearing on Sep 12, 2024; company had appealed earlier delisting determination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759186/000168316824006521/0001683168-24-006521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759186/000168316824006521/coeptis_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-006521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer